Methods for better identifying malignant versus benign disease before nephrectomy could provide significant benefits to patients and payers.
Trent McLaughlin, BSc(Pharm), PhD
Advertisement
Articles by Trent McLaughlin, BSc(Pharm), PhD
Advertisement
Latest Updated Articles
- Cost of Care for Malignant and Benign Renal Masses
Published: August 12th 2013 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Howard A. “Skip” Burris, III, MD: An Oncology Pioneer Reflects on Patients, Progress, and Purpose
2
New Bill Makes CMS Enforcer in PBM, Pharmacy Relationship: A Q&A With Jesse Dresser, Esq
3
Asundexian Cuts Recurrent Stroke Risk Without More Bleeding: Mukul Sharma, MD, MSc
4
Faricimab Safe, Effective for Use in Treating nAMD in Treatment-Naive Eyes
5